

## REMARKS

### Restriction Requirement

The Office imposed a restriction requirement consisting of two groups of inventions. To respond to the requirement, Applicants elect sets of compounds and compositions within Group I which are defined by the structures in Claims 54, 56 and 58 wherein specific substituents of the base steroid molecule are indicated.


The compounds elected from Group 1 of Claim 54 share a common structural feature and differ only by stereochemistry of the chosen substituents and the positioning of two double bonds and are therefore so similar as to be within the same inventive concept and enablement.

The compounds elected from Group 1 of Claim 56 share a common structural feature and differ only by stereochemistry of the chosen substituents and the positioning of two double bonds and are therefore so similar as to be within the same inventive concept and enablement.

The compounds elected from Group 1 of Claim 58 may be viewed as intermediates for preparation of the compounds of Claim 54 wherein the C17-position of the steroid nucleus is characterized by a (thio-) ketal substituent and wherein one or both hydroxyl substituents on the steroid nucleus are modified with an acyl group and are therefore so similar as to be within the same inventive concept and enablement.

The compositions of Claim 61 contain compounds for which election of species have been taken and are therefore also within the same inventive concept and enablement. Written description support is present in the specification for the new claims. To facilitate the Office's written description review, a list of exemplary written description support follows for the new claims.


<u>Claim</u>	<u>Support</u>
54	support is at paragraphs 009 through 026 and the original claims which provides substituents for the structure



wherein A is  $-\text{CR}^9\text{R}^{10}$ - wherein R<sup>9</sup> is OH and R<sup>10</sup> is ethynyl (para 20 line 7-(lower alkynyl)); E is  $-\text{CR}^5\text{R}^6$  wherein R<sup>5</sup> is H (para 17) and R<sup>6</sup> is H (para 18); K is  $-\text{CR}^1\text{R}^2$  wherein R<sup>1</sup> is OH (para 15 (R<sup>1</sup> is OR<sup>11</sup>)) and para 21 (R<sup>11</sup> is H)) and R<sup>2</sup> is H (para 16); G is  $=\text{CR}^3$  when the diene system is 1,6 or is  $-\text{CR}^3\text{R}^4$ - when the diene system is 1,7, 1,8, 1,15, or 4,8 wherein R<sup>3</sup> is H (para 17) and R<sup>4</sup> is H (para 18); wherein R<sup>7</sup> and R<sup>8</sup> is CH<sub>3</sub> (para 19) and wherein n and n' are 0 (para 25).

56

support is at paragraphs 027 through 043 and the original claims which provides substituents for the structure



wherein A is  $-\text{CR}^9\text{R}^{10}$ - wherein R<sup>9</sup> is OH and R<sup>10</sup> is ethynyl (para 37); E is  $-\text{CR}^5\text{R}^6$ - wherein R<sup>5</sup> is H (para 34) and R<sup>6</sup> is H (para 35); K is  $-\text{C}(\text{OR}^{11})\text{R}^2$ - when the diene system is 1,5 or is  $=\text{C}(\text{OR}^{11})$  when the diene system is 1,3; wherein R<sup>11</sup> is H (original claim 25) and R<sup>2</sup> is H (para 33); G is  $-\text{CR}^3\text{R}^4$ - wherein R<sup>3</sup> is OH (para 34) and R<sup>4</sup> (para 35) is H wherein R<sup>7</sup> and R<sup>8</sup> is CH<sub>3</sub> (para 36); wherein n and n' are 0 (para 42); wherein the dashed lines represent carbon-carbon double bonds or carbon-carbon single bond contained within the fused four ring system to include 1,3 and 1,5-diene systems (para 43).

58

support is as for claim 56 except the substituents R<sup>9</sup> and R<sup>10</sup> in  $-\text{CR}^9\text{R}^{10}$ - (para 11 (A is  $-\text{CR}^9\text{R}^{10}$ -) together with the carbon they are attached form a 5, 6 or 7-member heterocyclyl ring (para 99) wherein the heterocycle includes a 3 to 8 member ring containing 1 to 2 oxygen atoms or 1 to 3 sulfur atoms (para 78 lines 23-24 and lines 30-31) and R<sup>3</sup> in G is  $-\text{OC}(\text{O})\text{R}^{15}$  wherein R<sup>15</sup> is lower alkyl (para 34, 40).

60

support is as for claim 56 except A is  $-\text{C}(\text{O})$ - (para 29)

---

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 501536.

Respectfully submitted,

Hollis-Eden Pharmaceuticals, Inc.

Date: Nov 20, 2006 By: Angelo J. Castellino

Angelo J. Castellino, Reg. No. 52,707  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
P: 858-587-9333  
F: 858-558-6470